Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Engaging and Empowering Stakeholders to Advance Pharmacogenomics.

Crisamore KR, Nolin TD, Coons JC, Empey PE.

Clin Pharmacol Ther. 2019 Jun 26. doi: 10.1002/cpt.1470. [Epub ahead of print] No abstract available.

PMID:
31241758
2.

Factors Contributing to Fentanyl Pharmacokinetic Variability Among Diagnostically Diverse Critically Ill Children.

Hagos FT, Horvat CM, Au AK, Conley YP, Li L, Poloyac SM, Kochanek PM, Clark RSB, Empey PE.

Clin Pharmacokinet. 2019 Jun 6. doi: 10.1007/s40262-019-00773-1. [Epub ahead of print]

PMID:
31168770
3.

Confirmation of Selected Synergistic Cancer Drug Combinations Identified in an HTS Campaign and Exploration of Drug Efflux Transporter Contributions to the Mode of Synergy.

Kochanek SJ, Close DA, Wang AX, Shun T, Empey PE, Eiseman JL, Johnston PA.

SLAS Discov. 2019 Jul;24(6):653-668. doi: 10.1177/2472555219844566. Epub 2019 Apr 30.

PMID:
31039321
4.

Community pharmacists' educational needs for implementing clinical pharmacogenomic services.

Berenbrok LA, Hart KM, McGrath SH, Coley KC, Somma McGivney MA, Empey PE.

J Am Pharm Assoc (2003). 2019 Jul - Aug;59(4):539-544. doi: 10.1016/j.japh.2019.03.005. Epub 2019 Apr 19.

PMID:
31010787
5.

Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing.

Cavallari LH, Van Driest SL, Prows CA, Bishop JR, Limdi NA, Pratt VM, Ramsey LB, Smith DM, Tuteja S, Duong BQ, Hicks JK, Lee JC, Obeng AO, Beitelshees AL, Bell GC, Blake K, Crona DJ, Dressler L, Gregg RA, Hines LJ, Scott SA, Shelton RC, Weitzel KW, Johnson JA, Peterson JF, Empey PE, Skaar TC; IGNITE Network.

Genet Med. 2019 Mar 21. doi: 10.1038/s41436-019-0484-3. [Epub ahead of print]

PMID:
30894703
6.

Membrane transporters in traumatic brain injury: Pathological, pharmacotherapeutic, and developmental implications.

Hagos FT, Adams SM, Poloyac SM, Kochanek PM, Horvat CM, Clark RSB, Empey PE.

Exp Neurol. 2019 Jul;317:10-21. doi: 10.1016/j.expneurol.2019.02.011. Epub 2019 Feb 21. Review.

PMID:
30797827
7.

Design and testing of Medivate, a mobile app to achieve medication list portability via Fast Healthcare Interoperability Resources.

Coons JC, Patel R, Coley KC, Empey PE.

J Am Pharm Assoc (2003). 2019 Mar - Apr;59(2S):S78-S85.e2. doi: 10.1016/j.japh.2019.01.001. Epub 2019 Feb 5.

PMID:
30737102
8.

Paths to Successful Translation of New Therapies for Severe Traumatic Brain Injury in the Golden Age of Traumatic Brain Injury Research: A Pittsburgh Vision.

Kochanek PM, Jackson TC, Jha RM, Clark RSB, Okonkwo DO, Bayır H, Poloyac SM, Wagner AK, Empey PE, Conley YP, Bell MJ, Kline AE, Bondi CO, Simon DW, Carlson SW, Puccio AM, Horvat CM, Au AK, Elmer J, Treble-Barna A, Ikonomovic MD, Shutter LA, Taylor DL, Stern AM, Graham SH, Kagan VE, Jackson EK, Wisniewski SR, Dixon CE.

J Neurotrauma. 2019 Feb 1. doi: 10.1089/neu.2018.6203. [Epub ahead of print]

PMID:
30520681
9.

Therapeutic Hypothermia in Cardiac Arrest.

Noc M, Friberg H, Huang CH, Empey PE.

Ther Hypothermia Temp Manag. 2018 Dec;8(4):195-198. doi: 10.1089/ther.2018.29051.mjn. Epub 2018 Nov 9. No abstract available.

PMID:
30412452
10.

Usefulness of Intravenous Sodium Nitrite During Resuscitation for the Treatment of Out-of-Hospital Cardiac Arrest.

Kim F, Dezfulian C, Empey PE, Morrell M, Olsufka M, Scruggs S, Kudenchuk P, May S, Maynard C, Sayre MR, Nichol G.

Am J Cardiol. 2018 Aug 15;122(4):554-559. doi: 10.1016/j.amjcard.2018.04.060. Epub 2018 Jun 20.

PMID:
30205886
11.

Multi-Center Pre-clinical Consortia to Enhance Translation of Therapies and Biomarkers for Traumatic Brain Injury: Operation Brain Trauma Therapy and Beyond.

Kochanek PM, Dixon CE, Mondello S, Wang KKK, Lafrenaye A, Bramlett HM, Dietrich WD, Hayes RL, Shear DA, Gilsdorf JS, Catania M, Poloyac SM, Empey PE, Jackson TC, Povlishock JT.

Front Neurol. 2018 Aug 7;9:640. doi: 10.3389/fneur.2018.00640. eCollection 2018. Review.

12.

Clinical Pharmacogenomics: Applications in Nephrology.

Adams SM, Crisamore KR, Empey PE.

Clin J Am Soc Nephrol. 2018 Oct 8;13(10):1561-1571. doi: 10.2215/CJN.02730218. Epub 2018 May 23.

PMID:
29793969
13.

Exploratory Application of Neuropharmacometabolomics in Severe Childhood Traumatic Brain Injury.

Hagos FT, Empey PE, Wang P, Ma X, Poloyac SM, Bayir H, Kochanek PM, Bell MJ, Clark RSB.

Crit Care Med. 2018 Sep;46(9):1471-1479. doi: 10.1097/CCM.0000000000003203.

PMID:
29742587
14.

Regionally clustered ABCC8 polymorphisms in a prospective cohort predict cerebral oedema and outcome in severe traumatic brain injury.

Jha RM, Koleck TA, Puccio AM, Okonkwo DO, Park SY, Zusman BE, Clark RSB, Shutter LA, Wallisch JS, Empey PE, Kochanek PM, Conley YP.

J Neurol Neurosurg Psychiatry. 2018 Nov;89(11):1152-1162. doi: 10.1136/jnnp-2017-317741. Epub 2018 Apr 19.

PMID:
29674479
15.

Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.

Empey PE, Stevenson JM, Tuteja S, Weitzel KW, Angiolillo DJ, Beitelshees AL, Coons JC, Duarte JD, Franchi F, Jeng LJB, Johnson JA, Kreutz RP, Limdi NA, Maloney KA, Owusu Obeng A, Peterson JF, Petry N, Pratt VM, Rollini F, Scott SA, Skaar TC, Vesely MR, Stouffer GA, Wilke RA, Cavallari LH, Lee CR; IGNITE Network.

Clin Pharmacol Ther. 2018 Oct;104(4):664-674. doi: 10.1002/cpt.1006. Epub 2018 Jan 30.

PMID:
29280137
16.

Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.

Cavallari LH, Lee CR, Beitelshees AL, Cooper-DeHoff RM, Duarte JD, Voora D, Kimmel SE, McDonough CW, Gong Y, Dave CV, Pratt VM, Alestock TD, Anderson RD, Alsip J, Ardati AK, Brott BC, Brown L, Chumnumwat S, Clare-Salzler MJ, Coons JC, Denny JC, Dillon C, Elsey AR, Hamadeh IS, Harada S, Hillegass WB, Hines L, Horenstein RB, Howell LA, Jeng LJB, Kelemen MD, Lee YM, Magvanjav O, Montasser M, Nelson DR, Nutescu EA, Nwaba DC, Pakyz RE, Palmer K, Peterson JF, Pollin TI, Quinn AH, Robinson SW, Schub J, Skaar TC, Smith DM, Sriramoju VB, Starostik P, Stys TP, Stevenson JM, Varunok N, Vesely MR, Wake DT, Weck KE, Weitzel KW, Wilke RA, Willig J, Zhao RY, Kreutz RP, Stouffer GA, Empey PE, Limdi NA, Shuldiner AR, Winterstein AG, Johnson JA; IGNITE Network.

JACC Cardiovasc Interv. 2018 Jan 22;11(2):181-191. doi: 10.1016/j.jcin.2017.07.022. Epub 2017 Nov 1.

17.

The pharmacogenomics of severe traumatic brain injury.

Adams SM, Conley YP, Wagner AK, Jha RM, Clark RS, Poloyac SM, Kochanek PM, Empey PE.

Pharmacogenomics. 2017 Oct;18(15):1413-1425. doi: 10.2217/pgs-2017-0073. Epub 2017 Oct 4. Review.

18.

ABCG2 c.421C>A Is Associated with Outcomes after Severe Traumatic Brain Injury.

Adams SM, Conley YP, Ren D, Okonkwo DO, Puccio AM, Dixon CE, Clark RSB, Kochanek PM, Empey PE.

J Neurotrauma. 2018 Jan 1;35(1):48-53. doi: 10.1089/neu.2017.5000. Epub 2017 Sep 19.

19.

Precision Medicine in Critical Care Requires an Understanding of Pharmacokinetic Variability.

Empey PE.

Pediatr Crit Care Med. 2017 Jul;18(7):728-729. doi: 10.1097/PCC.0000000000001208. No abstract available.

PMID:
28691967
20.

Phase I randomized clinical trial of N-acetylcysteine in combination with an adjuvant probenecid for treatment of severe traumatic brain injury in children.

Clark RSB, Empey PE, Bayır H, Rosario BL, Poloyac SM, Kochanek PM, Nolin TD, Au AK, Horvat CM, Wisniewski SR, Bell MJ.

PLoS One. 2017 Jul 7;12(7):e0180280. doi: 10.1371/journal.pone.0180280. eCollection 2017.

21.

ABCB1 genotype is associated with fentanyl requirements in critically ill children.

Horvat CM, Au AK, Conley YP, Kochanek PM, Li L, Poloyac SM, Empey PE, Clark RSB.

Pediatr Res. 2017 Jul;82(1):29-35. doi: 10.1038/pr.2017.103. Epub 2017 May 31.

22.

Design and evaluation of a pharmacogenomics information resource for pharmacists.

Romagnoli KM, Boyce RD, Empey PE, Ning Y, Adams S, Hochheiser H.

J Am Med Inform Assoc. 2017 Jul 1;24(4):822-831. doi: 10.1093/jamia/ocx007.

23.

The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.

Cavallari LH, Beitelshees AL, Blake KV, Dressler LG, Duarte JD, Elsey A, Eichmeyer JN, Empey PE, Franciosi JP, Hicks JK, Holmes AM, Jeng L, Lee CR, Lima JJ, Limdi NA, Modlin J, Obeng AO, Petry N, Pratt VM, Skaar TC, Tuteja S, Voora D, Wagner M, Weitzel KW, Wilke RA, Peterson JF, Johnson JA.

Clin Transl Sci. 2017 May;10(3):143-146. doi: 10.1111/cts.12456. Epub 2017 Mar 14. Review. No abstract available.

24.

Educational strategies to enable expansion of pharmacogenomics-based care.

Weitzel KW, Aquilante CL, Johnson S, Kisor DF, Empey PE.

Am J Health Syst Pharm. 2016 Dec 1;73(23):1986-1998. Review.

25.

Pharmacogenomics to achieve precision medicine.

Empey PE.

Am J Health Syst Pharm. 2016 Dec 1;73(23):1906-1907. Epub 2016 Oct 26. No abstract available.

PMID:
27784662
26.

Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available.

Samwald M, Xu H, Blagec K, Empey PE, Malone DC, Ahmed SM, Ryan P, Hofer S, Boyce RD.

PLoS One. 2016 Oct 20;11(10):e0164972. doi: 10.1371/journal.pone.0164972. eCollection 2016.

27.

Probenecid and N-Acetylcysteine Prevent Loss of Intracellular Glutathione and Inhibit Neuronal Death after Mechanical Stretch Injury In Vitro.

Du L, Empey PE, Ji J, Chao H, Kochanek PM, Bayır H, Clark RS.

J Neurotrauma. 2016 Oct 15;33(20):1913-1917. Epub 2016 Mar 22.

28.

ABCC8 Single Nucleotide Polymorphisms are Associated with Cerebral Edema in Severe TBI.

Jha RM, Puccio AM, Okonkwo DO, Zusman BE, Park SY, Wallisch J, Empey PE, Shutter LA, Clark RS, Kochanek PM, Conley YP.

Neurocrit Care. 2017 Apr;26(2):213-224. doi: 10.1007/s12028-016-0309-z.

29.
30.

Probenecid, an organic anion transporter 1 and 3 inhibitor, increases plasma and brain exposure of N-acetylcysteine.

Hagos FT, Daood MJ, Ocque JA, Nolin TD, Bayir H, Poloyac SM, Kochanek PM, Clark RS, Empey PE.

Xenobiotica. 2017 Apr;47(4):346-353. doi: 10.1080/00498254.2016.1187777. Epub 2016 Jun 9.

31.

Advancing Pharmacogenomics Education in the Core PharmD Curriculum through Student Personal Genomic Testing.

Adams SM, Anderson KB, Coons JC, Smith RB, Meyer SM, Parker LS, Empey PE.

Am J Pharm Educ. 2016 Feb 25;80(1):3. doi: 10.5688/ajpe8013.

32.

Bringing clinical pharmacogenomics information to pharmacists: A qualitative study of information needs and resource requirements.

Romagnoli KM, Boyce RD, Empey PE, Adams S, Hochheiser H.

Int J Med Inform. 2016 Feb;86:54-61. doi: 10.1016/j.ijmedinf.2015.11.015. Epub 2015 Nov 30.

33.

Synthesis of Findings, Current Investigations, and Future Directions: Operation Brain Trauma Therapy.

Kochanek PM, Bramlett HM, Shear DA, Dixon CE, Mondello S, Dietrich WD, Hayes RL, Wang KK, Poloyac SM, Empey PE, Povlishock JT, Mountney A, Browning M, Deng-Bryant Y, Yan HQ, Jackson TC, Catania M, Glushakova O, Richieri SP, Tortella FC.

J Neurotrauma. 2016 Mar 15;33(6):606-14. doi: 10.1089/neu.2015.4133. Review.

PMID:
26671284
34.

Cyclosporine Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy.

Dixon CE, Bramlett HM, Dietrich WD, Shear DA, Yan HQ, Deng-Bryant Y, Mondello S, Wang KK, Hayes RL, Empey PE, Povlishock JT, Tortella FC, Kochanek PM.

J Neurotrauma. 2016 Mar 15;33(6):553-66. doi: 10.1089/neu.2015.4122.

PMID:
26671075
35.

Simvastatin Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy.

Mountney A, Bramlett HM, Dixon CE, Mondello S, Dietrich WD, Wang KK, Caudle K, Empey PE, Poloyac SM, Hayes RL, Povlishock JT, Tortella FC, Kochanek PM, Shear DA.

J Neurotrauma. 2016 Mar 15;33(6):567-80. doi: 10.1089/neu.2015.4130. Epub 2016 Jan 20.

PMID:
26541177
36.

Dexmedetomidine Reduces Shivering during Mild Hypothermia in Waking Subjects.

Callaway CW, Elmer J, Guyette FX, Molyneaux BJ, Anderson KB, Empey PE, Gerstel SJ, Holquist K, Repine MJ, Rittenberger JC.

PLoS One. 2015 Aug 3;10(8):e0129709. doi: 10.1371/journal.pone.0129709. eCollection 2015.

37.

Expression of ATP-Binding Cassette Transporters B1 and C1 after Severe Traumatic Brain Injury in Humans.

Willyerd FA, Empey PE, Philbrick A, Ikonomovic MD, Puccio AM, Kochanek PM, Okonkwo DO, Clark RS.

J Neurotrauma. 2016 Jan 15;33(2):226-31. doi: 10.1089/neu.2015.3879. Epub 2015 Jun 17.

38.

Emerging therapies in traumatic brain injury.

Kochanek PM, Jackson TC, Ferguson NM, Carlson SW, Simon DW, Brockman EC, Ji J, Bayır H, Poloyac SM, Wagner AK, Kline AE, Empey PE, Clark RS, Jackson EK, Dixon CE.

Semin Neurol. 2015 Feb;35(1):83-100. doi: 10.1055/s-0035-1544237. Epub 2015 Feb 25. Review.

39.

In vitro transport characteristics of EFdA, a novel nucleoside reverse transcriptase inhibitor using Caco-2 and MDCKII cell monolayers.

Zhang W, Parniak MA, Sarafianos SG, Empey PE, Rohan LC.

Eur J Pharmacol. 2014 Jun 5;732:86-95. doi: 10.1016/j.ejphar.2014.03.022. Epub 2014 Mar 29.

40.

Patient predictors of dexmedetomidine effectiveness for sedation in intensive care units.

Smithburger PL, Smith RB, Kane-Gill SL, Empey PE.

Am J Crit Care. 2014 Mar;23(2):160-5. doi: 10.4037/ajcc2014678.

41.

Interpatient variability in dexmedetomidine response: a survey of the literature.

Holliday SF, Kane-Gill SL, Empey PE, Buckley MS, Smithburger PL.

ScientificWorldJournal. 2014 Jan 16;2014:805013. doi: 10.1155/2014/805013. eCollection 2014. Review.

42.

Toward semantic modeling of pharmacogenomic knowledge for clinical and translational decision support.

Boyce RD, Freimuth RR, Romagnoli KM, Pummer T, Hochheiser H, Empey PE.

AMIA Jt Summits Transl Sci Proc. 2013 Mar 18;2013:28-32. eCollection 2013.

43.

Therapeutic hypothermia decreases phenytoin elimination in children with traumatic brain injury.

Empey PE, Velez de Mendizabal N, Bell MJ, Bies RR, Anderson KB, Kochanek PM, Adelson PD, Poloyac SM; Pediatric TBI Consortium: Hypothermia Investigators.

Crit Care Med. 2013 Oct;41(10):2379-87. doi: 10.1097/CCM.0b013e318292316c.

44.

Influence of ATP-binding cassette polymorphisms on neurological outcome after traumatic brain injury.

Cousar JL, Conley YP, Willyerd FA, Sarnaik AA, Puccio AM, Empey PE, Kochanek PM, Bell MJ, Okonkwo DO, Clark RS.

Neurocrit Care. 2013 Oct;19(2):192-8. doi: 10.1007/s12028-013-9881-7.

45.

Drug dosing during hypothermia: to adjust, or not to adjust, that is the question.

Poloyac SM, Empey PE.

Pediatr Crit Care Med. 2013 Feb;14(2):228-9. doi: 10.1097/PCC.0b013e31826775cd. No abstract available.

46.

Stereoselective interaction of pantoprazole with ABCG2. II. In vitro flux analysis.

Wang L, Leggas M, Empey PE, McNamara PJ.

Drug Metab Dispos. 2012 May;40(5):1024-31. doi: 10.1124/dmd.111.041616. Epub 2012 Feb 21.

47.

Mild hypothermia decreases fentanyl and midazolam steady-state clearance in a rat model of cardiac arrest.

Empey PE, Miller TM, Philbrick AH, Melick JA, Kochanek PM, Poloyac SM.

Crit Care Med. 2012 Apr;40(4):1221-8. doi: 10.1097/CCM.0b013e31823779f9.

48.

Cardiac arrest and therapeutic hypothermia decrease isoform-specific cytochrome P450 drug metabolism.

Zhou J, Empey PE, Bies RR, Kochanek PM, Poloyac SM.

Drug Metab Dispos. 2011 Dec;39(12):2209-18. doi: 10.1124/dmd.111.040642. Epub 2011 Aug 25.

49.

Core competencies for research training in the clinical pharmaceutical sciences.

Poloyac SM, Empey KM, Rohan LC, Skledar SJ, Empey PE, Nolin TD, Bies RR, Gibbs RB, Folan M, Kroboth PD.

Am J Pharm Educ. 2011 Mar 10;75(2):27.

50.

Endothelin-1 is increased in cerebrospinal fluid and associated with unfavorable outcomes in children after severe traumatic brain injury.

Salonia R, Empey PE, Poloyac SM, Wisniewski SR, Klamerus M, Ozawa H, Wagner AK, Ruppel R, Bell MJ, Feldman K, Adelson PD, Clark RS, Kochanek PM.

J Neurotrauma. 2010 Oct;27(10):1819-25. doi: 10.1089/neu.2010.1402. Epub 2010 Sep 17.

Supplemental Content

Loading ...
Support Center